SEC Info - Opexa Therapeutics, Inc. - ‘8-K’ for 9/12/16

SEC Info℠

Home

Help

Please Sign In

Opexa Therapeutics, Inc. – ‘8-K’ for 9/12/16

On: Monday, 9/12/16, at 8:30am ET · For: 9/12/16 · Accession #: 1654954-16-2135 · File #: 1-33004

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 9/12/16  Opexa Therapeutics, Inc.          8-K:7,9     9/12/16    2:2.9M                                   Blueprint/FA

Current Report — Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     19K 
 2: EX-99.1     Investor Presentation                               HTML     15K

8-K — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

Blueprint

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): September 12, 2016

OPEXA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Texas		001-33004		76-0333165
(State or other jurisdiction ofincorporation)		(Commission File Number)		(IRS Employer Identification No.)

2635 Technology Forest Blvd., The Woodlands, Texas		77381
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (281) 272-9331

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Opexa Therapeutics, Inc. (the “Company”) has updated its Investor Presentation that will be available on the Investor Relations page of the Company’s website (www.opexatherapeutics.com) and will be used at investor and other meetings. A copy of the updated Investor Presentation is furnished as Exhibit 99.1 and incorporated herein by reference. The Company does not undertake to update this presentation.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Opexa Therapeutics, Inc. Investor Presentation, September 2016.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities under that Section, nor be deemed to be incorporated by reference into the filings of the registrant under the Securities Act of 1933.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OPEXA THERAPEUTICS, INC.

Dated: September 12, 2016	By:	/s/ *Neil K. Warma*
		Neil K. Warma
		President, Chief Executive Officer and Acting Chief Financial Officer

EXHIBIT INDEX

Exhibit No.		Description
99.1		Opexa Therapeutics, Inc. Investor Presentation, September 2016.

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period End:	9/12/16	None on these Dates
		List all Filings

↑Top

Filing Submission 0001654954-16-002135 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)